JPMorgan reiterates overweight rating on Phreesia stock amid growth

Published 25/06/2025, 13:58
JPMorgan reiterates overweight rating on Phreesia stock amid growth

Investing.com - JPMorgan maintained its overweight rating on Phreesia Inc . (NYSE:PHR) following a fireside chat with the company’s CFO Balaji Gandhi. The healthcare software company, currently valued at $1.66 billion, has seen its stock surge 8.61% in the past week, trading near $27.87.

The investment bank expressed encouragement about Phreesia’s fiscal year 2026 growth algorithm, which it believes provides a reasonable forward basis for the healthcare software company’s performance. According to InvestingPro data, the company maintains a robust gross profit margin of 68.02% and has achieved 16.29% revenue growth in the last twelve months.

JPMorgan noted Phreesia’s total addressable market (TAM) expansion opportunities as the company continues to invest in its platform development, potentially opening new revenue streams.

The firm highlighted that Phreesia’s revenue diversification strategy provides some insulation from macroeconomic challenges, creating a more resilient business model.

JPMorgan’s analysis comes amid what it described as "continued investor interest" in Phreesia, alongside the company’s "recent rapid ramp in profitability," factors that appear to be supporting the maintained overweight rating.

In other recent news, Phreesia Inc. reported its first-quarter earnings, showing strong financial performance that surpassed expectations. The company achieved $115.9 million in revenue, a 15% year-over-year increase, beating the consensus estimate of $114.9 million. Adjusted EBITDA reached $20.8 million, significantly surpassing the expected $16 million. In response, several firms have maintained their positive outlooks on Phreesia. Piper Sandler kept an Overweight rating with a $33 price target, acknowledging the company’s improved EBITDA forecast. Similarly, JPMorgan maintained an Overweight rating with a $30 target, highlighting Phreesia’s healthy revenue growth projections for fiscal year 2026. Canaccord Genuity adjusted its price target to $34 from $35, while still holding a Buy rating, noting the company’s strong growth and profitability metrics. DA Davidson also reiterated a Buy rating with a $34 target, emphasizing Phreesia’s potential for profit growth despite challenges in the Network Solutions segment. Raymond (NSE:RYMD) James maintained an Outperform rating with a $30 target, expressing confidence in the company’s strategic investments and financial discipline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.